JMDSJournal of Medicines Development Sciences2382-63632382-6371WHIOCE PUBLISHING PTE. LTD.10.18063/jmds.v7i1.139ArticleDevelopment of Novel Drugs to Promote Functional Recovery After Brain Injuryhttps://artdesignp.com/journal/JMDS/7/1/10.18063/jmds.v7i1.139NakajimaWaki,TakahashiTakuya2023712023-08-23The central nervous system injury such as stroke can severely cause motor paralysis.Although the approach of rehabilitative training is developed, many patients still face restrictions in their daily living after rehabilitation. Thereby, a new compound with a strong potential to enhance motor function recovery with rehabilitation is an unmet medical need. We focus on the one of glutamate receptors, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, which plays an important role in learning and memory. Here, we found a novel small low molecular compound, edonerpic maleate, that facilitated experience-dependent synaptic AMPA receptor delivery in the barrel cortex and dramatically accelerated motor function recovery after brain damage in a rodent model. Furthermore, edonerpic maleate enhanced the upper limb function recovery of macaque monkeys with internal capsule hemorrhage. Currently, a phase 2 clinical trial is being conducted to verify the efficacy of edonerpic maleate in stroke patients and has attracted global attention.AMPA receptors, Brain injury, Functional recovery, Neural plasticity

1. Nudo RJ, Wise BM, SiFuentes F, et al. Neural Substrates for the Effects of Rehabilitative Training on Motor Recovery After Ischemic Infarct. Science, 272: 1791–1794. 1996.2. Murata Y, Higo N, Oishi T, et al. Effects of Motor Training on the Recovery of Manual Dexterity After Primary Motor Cortex Lesion in Macaque Monkeys. J Neurophysiol, 99: 773–786. 2008.3. Murata Y, Higo N, Hayashi T, et al. Temporal Plasticity Involved in Recovery From Manual Dexterity Deficit After Motor Cortex Lesion in Macaque Monkeys. J Neurosci, 35: 84–95. 2015.4. Ishida A, Isa K, Umeda T, et al. Causal Link between the Cortico-Rubral Pathway and Functional Recovery through Forced Impaired Limb Use in Rats with Stroke. J Neurosci, 36: 455–467. 2016.5. Ueno M, Hayano Y, Nakagawa H, et al. Intraspinal Rewiring of the Corticospinal Tract Requires Target-Derived Brain-Derived Neurotrophic Factor and Compensates Lost Function After Brain Injury. Brain, 135: 1253–1267. 2012.6. Abe H, Jitsuki S, Nakajima W, et al. CRMP2-Binding Compound, Edonerpic Maleate, Accelerates Motor Function Recovery From Brain Damage. Science, 360: 50–57. 2018.7. Abe H, Jitsuki S, Takahashi T. Pharmacological Enhancement of Stroke Rehabilitation. Stroke, 50: 3323–3329. 2019.8. Kumar A, Kitago T. Pharmacological Enhancement of Stroke Recovery. Curr Neurol Neurosci Rep, 19: 43. 2019.9. Xu SY, Pan SY. The Failure of Animal Models of Neuroprotection in Acute Ischemic Stroke to Translate to Clinical Efficacy. Med Sci Monit Basic Res, 19: 37–45. 2013.10. Lyden P, Pryor KE, Coffey CS, et al. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann Neurol, 85: 125–136. 2019.11. Hill MD, Martin RH, Mikulis D, et al. Safety and Efficacy of NA-1 in Patients With Iatrogenic Stroke After Endovascular Aneurysm Repair (ENACT): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Neurology, 11: 942–950. 2012.12. Hill MD, Goyal M, Menon BK, et al. Efficacy and Safety of Nerinetide for the Treatment of Acute Ischaemic Stroke (ESCAPE-NA1): A Multicentre, Double-Blind, Randomised Controlled Trial. The Lancet, 395: 878–887. 2020.13. Goldstein LB, Lennihan L, Rabadi MJ, et al. Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial. JAMA Neurol, 75: 1494–1501. 2018.14. Scheidtmann K, Fries W, Müller F, et al. Effect of Levodopa in Combination With Physiotherapy on Functional Motor Recovery After Stroke: A Prospective, Randomised, Double-Blind Study. The Lancet, 358: 787–790. 2001.15. Restemeyer C, Weiller C, Liepert J. No Effect of a Levodopa Single Dose on Motor Performance and Motor Excitability in Chronic Stroke. A Double-Blind Placebo-Controlled Cross-Over Pilot Study. Restor Neurol Neurosci, 25: 143–150. 2007.16. Chollet F, Tardy J, Albucher J-F, et al. Fluoxetine for Motor Recovery after Acute Ischaemic Stroke (FLAME): A Randomised Placebo-Controlled Trial. The Lancet Neurology, 10: 123–130. 2011.17. FOCUS Trial Collaboration. Effects of Fluoxetine on Functional Outcomes After Acute Stroke (FOCUS): A Pragmatic, Double-Blind, Randomised, Controlled Trial. The Lancet, 393: 265–274. 2019.18. Cash D, Easton AC, Mesquita M, et al. GSK249320, a Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci, 2: 28–33. 2016.19. Cramer SC, Enney LA, Russell CK, et al. Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients. Stroke, 48: 692–698. 2017.20. Joy MT, Ben Assayag E, Shabashov-Stone D, et al. CCR5 is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury. Cell, 176: 1143–1157 e1113. 2019.21. Rosand J, Khatri P, Lee J-M. Recovery from Brain Injury: A Surprising New Drug Target. The Lancet Neurology, 18: 421–422. 2019.22. Cooke SF, Bliss TV. Plasticity in the Human Central Nervous System. Brain, 129: 1659–1673. 2006.23. Shi SH, Hayashi Y, Petralia RS, et al. Rapid Spine Delivery And Redistribution of AMPA Receptors After Synaptic NMDA Receptor Activation. Science, 284: 1811–1816. 1999.24. Hayashi Y, Shi SH, Esteban JA, et al. Driving AMPA Receptors Into Synapses by LTP and Camkii: Requirement for Glur1 and PDZ Domain Interaction. Science, 287: 2262–2267. 2000.25. Takahashi T, Svoboda K, Malinow R. Experience strengthening transmission by driving AMPA receptors into synapses. Science, 299: 1585–1588. 2003.26. Kida H, Tsuda Y, Ito N, et al. Motor Training Promotes Both Synaptic and Intrinsic Plasticity of Layer II/III Pyramidal Neurons in the Primary Motor Cortex. Cereb Cortex, 26: 3494–3507. 2016.27. Clarkson AN, Overman JJ, Zhong S, et al. AMPA Receptor-Induced Local Brain-Derived Neurotrophic Factor Signaling Mediates Motor Recovery After Stroke. J Neurosci, 31: 3766–3775. 2011.28. Tamakoshi K, Ishida K, Kawanaka K, et al. Motor Skills Training Enhances Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Subunit mRNA Expression in the Ipsilateral Sensorimotor Cortex and Striatum of Rats Following Intracerebral Hemorrhage. J Stroke Cerebrovasc Dis, 26: 2232–2239. 2017.29. Hirata K, Yamaguchi H, Takamura Y, et al. A Novel Neurotrophic Agent, T-817MA [1-{3-[2-(1-Benzothiophen-5yl)Ethoxy]Propyl}-3-Azetidinol Maleate], Attenuates Amyloid-Beta-Induced Neurotoxicity and Promotes Neurite Outgrowth in Rat Cultured Central Nervous System Neurons. J Pharmacol Exp Ther, 314: 252–259. 2005.30. Seward ME, Swanson E, Norambuena A, et al. Amyloid-Beta Signals Through Tau to Drive Ectopic Neuronal Cell Cycle Re-Entry in Alzheimer’s Disease. J Cell Sci, 126: 1278–1286. 2013.31. Schneider LS, Thomas RG, Hendrix S, et al. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol, 76(11): 1330–1339. 2019.32. Goshima Y, Nakamura F, Strittmatter P, et al. Collapsin-Induced Growth Cone Collapse Mediated by an Intracellular Protein Related to UNC-33. Nature, 376: 509–514. 1995.33. Jin X, Sasamoto K, Nagai J, et al. Phosphorylation of CRMP2 by Cdk5 Regulates Dendritic Spine Development of Cortical Neuron in the Mouse Hippocampus. Neural Plast, 2016: 6790743. 2016.